// App-Quantinova.ai

2585 : Clinical pharmacokinetic (PK)/pharmacodynamic (PD) model for Debio 1143, a novel antagonist of IAPs in cancer treatment.

Researchers

Presenter

  • Elisabeth Rouits

Principal Investigators

  • Per Olsson Gisleskog

  • Claudio Zanna

  • Gregoire Vuagniaux

  • Valerie Nicolas-Metral

  • Bruno Gavillet

  • Annick Menetrey

  • Mel Sorensen

Medical Centers

  • Exprimo NV, Mechelen, Belgium

  • Debiopharm International SA, Lausanne, SwitzerlandAscenta Therapeutics Inc., Malvern, PA

Locations

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Ascenta Therapeutics, Inc.

  • Debiopharm

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved